Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ABO2011 alone and in combination with toripalimab in advanced solid tumors
CTR20240149Phase 2Active
- Sponsor
- Abogen Bioscience
- Start
- Oct 2023
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of ABO2011 in Nonhematologic neoplasms (2 arms), sponsored by Abogen Bioscience. Started Oct 2023; status: active.
02
Drugs
ABO2011
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20240149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240149.